Ponvory

The French company Juvisé Pharmaceuticals has acquired the rights to develop and market the approved multiple sclerosis (MS) therapy Ponvory (ponesimod) outside the U.S. and Canada. The global rights were acquired from Actelion Pharmaceuticals, the therapy’s original developer and now part of Johnson & Johnson Innovative Medicine.

The U.S. Patent and Trademark Office (USPTO) has notified Vanda Pharmaceuticals that it will grant a new patent covering the use of Ponvory (ponesimod), an approved oral treatment for relapsing forms of multiple sclerosis (MS), that will span nearly two decades, the company announced. The upcoming patent specifically…

Vanda Pharmaceuticals has acquired the U.S. and Canadian rights to Ponvory (ponesimod), an oral therapy approved for relapsing types of MS, in a new deal with Actelion Pharmaceuticals. Under the terms of the agreement, Vanda paid $100 million to Actelion (now part of Janssen), the therapy’s original developer. While…

The approved dosage of the multiple sclerosis (MS) therapy Ponvory (ponesimod) — 20 mg taken by mouth once daily — is appropriate for all adults with relapsing forms of MS, a new analysis of data from the OPTIMUM Phase 3 trial found. That analysis showed there was no…

Long-term treatment with Ponvory (ponesimod) safely and effectively reduces the rate of relapses, slows disability worsening, and prevents brain volume decline in adults with relapsing-remitting multiple sclerosis (RRMS). That’s according to eight years of data from patients enrolled in a now-completed Phase 2 clinical trial (NCT01006265) and its…

Novartis’ Mayzent (siponimod) and Kesimpta (ofatumumab) are gaining ground among multiple sclerosis (MS) therapies in Canada, according to the latest Spherix Global Insights’ report. “Following an eventful 2021 that included the launch of two new brands — Novartis’ Kesimpta and BMS’ Zeposia — and generic versions of Biogen’s…

Treatment with Ponvory (ponesimod) significantly reduces the risk of worsening disability or new relapses for people with relapsing forms of multiple sclerosis (MS) compared with a placebo, according to a new analysis funded by the therapy’s maker Janssen. The study, “Comparative Efficacy of Relapsing Multiple Sclerosis Therapies:…

For the first time, researchers have brought to light the precise three-dimensional structure of Mayzent (siponimod) as it binds to its molecular target, the sphingosine 1-phosphate receptor 1 (S1P1). These findings are expected to aid in developing next-generation MS therapeutics with better selectivity for S1P1, enhancing their potency while reducing…

Multiple Sclerosis News Today brought you daily coverage of the latest scientific research, advances in treatment, and clinical trials related to multiple sclerosis (MS) throughout 2021. We look forward to continuing to be a resource for the MS community in 2022. Here are the Top 10 most-read articles of…

Note: This story was updated Jan. 12, 2022, to note that Ponvory is approved in the U.K. for people with relapsing forms of MS who have active disease, defined by clinical or imaging features. The National Institute for Health and Care Excellence (NICE) has recommended that Ponvory (ponesimod)…

Tecfidera (dimethyl fumarate) and Aubagio (teriflunomide) are the preferred disease-modifying treatments for managing relapsing-remitting multiple sclerosis (RRMS) in Canada, according to a report from Spherix Global Insights. The report was part of Spherix’s RealTime Dynamix: Multiple Sclerosis (Canada) service, which collects data on market trends of MS…

The Scottish Medicines Consortium (SMC) has recommended that Ponvory (ponesimod) be offered through the National Health Service (NHS) Scotland to people with active, relapsing forms of multiple sclerosis (MS). The decision means that the oral therapy will be available at low or no cost to patients with clinically isolated syndrome (CIS),…

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the conference.

The National Institute for Health and Care Excellence (NICE) will not recommend that Ponvory (ponesimod) be added to the National Health Service (NHS) of England and Wales for people with active, relapsing forms of multiple sclerosis (MS). The provisional decision, made because Ponvory was not found to be…

In the OPTIMUM clinical trial, Ponvory (ponesimod) significantly outperformed Aubagio (teriflunomide) in reducing relapse rates, fatigue, and evidence of brain damage among people with relapsing multiple sclerosis (MS). Based on these results, Ponvory has now been approved in the U.S. and the European Union as a treatment…

Mayzent (siponimod) and Zeposia (ozanimod), the two sphingosine-1-phosphate (S1P) receptor modulators most recently approved in Canada for treating multiple sclerosis (MS), showed strong launches in the country, according to the latest Spherix Global Insights’ report. However, due to several internal and external factors, sustained relevance of these…

The European Commission has approved Ponvory (ponesimod) to treat adults with relapsing forms of multiple sclerosis (MS) and active disease, as defined by clinical or imaging features. The approval, which follows a recommendation from the Committee for Medicinal Products for Human Use in March, covers clinically isolated…

A branch of the European Medicines Agency has recommended that Ponvory (ponesimod) be approved to treat relapsing forms of multiple sclerosis (MS) in adults with active disease. This positive opinion from agency’s Committee for Medicinal Products for Human Use (CHMP) covers clinically isolated syndrome, relapsing-remitting MS (RRMS), and active secondary…

The U.S. Food and Drug Administration (FDA) has approved Ponvory (ponesimod) as an oral treatment for adults with relapsing forms of multiple sclerosis (MS). The approval covers clinically isolated syndrome, relapsing-remitting MS (RRMS), and active secondary progressive MS (SPMS). The treatment is taken as a…